Molecular heterogeneity and treatment outcome of EGFR exon 20 insertion mutations in Chinese patients with advanced non-small cell lung cancer: insights from a large-scale real-world study

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: 1 Online-Ressource.

Language: Englisch

Bibliographic citation: Molecular heterogeneity and treatment outcome of EGFR exon 20 insertion mutations in Chinese patients with advanced non-small cell lung cancer: insights from a large-scale real-world study ; volume:24 ; number:1 ; day:14 ; month:8 ; year:2024 ; pages:1-12 ; date:12.2024
BMC cancer ; 24, Heft 1 (14.8.2024), 1-12, 12.2024

Creator: Wu, Weirui
Yu, Silin
Huang, Jinsheng
Qi, Qi
Wu, Yongyi
Dong, Jun

Contributor: SpringerLink (Online service)

DOI: 10.1186/s12885-024-12773-x

URN: urn:nbn:de:101:1-2411041059266.156136903234

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:28 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Wu, Weirui
Yu, Silin
Huang, Jinsheng
Qi, Qi
Wu, Yongyi
Dong, Jun
SpringerLink (Online service)

Other Objects (12)

Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer

Aufsatzsammlung

EGFR exon 20 insertion mutations in NSCLC

Non-small Cell Lung Cancer with EGFR or HER2 Exon 20 Insertion Mutations: Diagnosis and Treatment Options

Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma

EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer

EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectives

A phase 2 study of mobocertinib as first-line treatment in Japanese patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations

Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M

Unmet needs in EGFR exon 20 insertion mutations in Central and Eastern Europe: reimbursement, diagnostic procedures, and treatment availability

Optimal therapy for concomitant EGFR and TP53 mutated non-small cell lung cancer: a real-world study

The benefit of anti-angiogenic therapy in EGFR exon 21 L858R mutant non-small cell lung cancer patients: a retrospective study

A real-world study of Afatinib plus ramucirumab in treatment-naïve, EGFR-mutated, non–small cell lung cancer

Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer

Aufsatzsammlung

EGFR exon 20 insertion mutations in NSCLC

Non-small Cell Lung Cancer with EGFR or HER2 Exon 20 Insertion Mutations: Diagnosis and Treatment Options

Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma

EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer

EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectives

A phase 2 study of mobocertinib as first-line treatment in Japanese patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations

Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M

Unmet needs in EGFR exon 20 insertion mutations in Central and Eastern Europe: reimbursement, diagnostic procedures, and treatment availability

Optimal therapy for concomitant EGFR and TP53 mutated non-small cell lung cancer: a real-world study

The benefit of anti-angiogenic therapy in EGFR exon 21 L858R mutant non-small cell lung cancer patients: a retrospective study

A real-world study of Afatinib plus ramucirumab in treatment-naïve, EGFR-mutated, non–small cell lung cancer

Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer

Aufsatzsammlung

EGFR exon 20 insertion mutations in NSCLC

Non-small Cell Lung Cancer with EGFR or HER2 Exon 20 Insertion Mutations: Diagnosis and Treatment Options

Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma

EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer

EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectives

A phase 2 study of mobocertinib as first-line treatment in Japanese patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations

Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M

Unmet needs in EGFR exon 20 insertion mutations in Central and Eastern Europe: reimbursement, diagnostic procedures, and treatment availability

Optimal therapy for concomitant EGFR and TP53 mutated non-small cell lung cancer: a real-world study

The benefit of anti-angiogenic therapy in EGFR exon 21 L858R mutant non-small cell lung cancer patients: a retrospective study

A real-world study of Afatinib plus ramucirumab in treatment-naïve, EGFR-mutated, non–small cell lung cancer

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Molecular heterogeneity and treatment outcome of EGFR exon 20 insertion mutations in Chinese patients with advanced non-small cell lung cancer: insights from a large-scale real-world study

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer

EGFR exon 20 insertion mutations in NSCLC

Non-small Cell Lung Cancer with EGFR or HER2 Exon 20 Insertion Mutations: Diagnosis and Treatment Options

Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma

EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer

EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectives

A phase 2 study of mobocertinib as first-line treatment in Japanese patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations

Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M

Unmet needs in EGFR exon 20 insertion mutations in Central and Eastern Europe: reimbursement, diagnostic procedures, and treatment availability

Optimal therapy for concomitant EGFR and TP53 mutated non-small cell lung cancer: a real-world study

The benefit of anti-angiogenic therapy in EGFR exon 21 L858R mutant non-small cell lung cancer patients: a retrospective study

A real-world study of Afatinib plus ramucirumab in treatment-naïve, EGFR-mutated, non–small cell lung cancer

Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer

EGFR exon 20 insertion mutations in NSCLC

Non-small Cell Lung Cancer with EGFR or HER2 Exon 20 Insertion Mutations: Diagnosis and Treatment Options

Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma

EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer

EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectives

A phase 2 study of mobocertinib as first-line treatment in Japanese patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations

Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M

Unmet needs in EGFR exon 20 insertion mutations in Central and Eastern Europe: reimbursement, diagnostic procedures, and treatment availability

Optimal therapy for concomitant EGFR and TP53 mutated non-small cell lung cancer: a real-world study

The benefit of anti-angiogenic therapy in EGFR exon 21 L858R mutant non-small cell lung cancer patients: a retrospective study

A real-world study of Afatinib plus ramucirumab in treatment-naïve, EGFR-mutated, non–small cell lung cancer

Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer

EGFR exon 20 insertion mutations in NSCLC

Non-small Cell Lung Cancer with EGFR or HER2 Exon 20 Insertion Mutations: Diagnosis and Treatment Options

Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma

EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer

EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectives

A phase 2 study of mobocertinib as first-line treatment in Japanese patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations

Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M

Unmet needs in EGFR exon 20 insertion mutations in Central and Eastern Europe: reimbursement, diagnostic procedures, and treatment availability

Optimal therapy for concomitant EGFR and TP53 mutated non-small cell lung cancer: a real-world study

The benefit of anti-angiogenic therapy in EGFR exon 21 L858R mutant non-small cell lung cancer patients: a retrospective study

A real-world study of Afatinib plus ramucirumab in treatment-naïve, EGFR-mutated, non–small cell lung cancer

Related objects

Reset password